Pharmacology of Tetracyclines and Chloramphenicol

Introduction/Overview

The tetracyclines and chloramphenicol represent two distinct but historically significant classes of broad-spectrum, bacteriostatic antibiotics. Their discovery in the mid-20th century marked a pivotal advancement in antimicrobial chemotherapy, providing effective tools against a wide array of pathogens, including intracellular organisms. While their clinical use has been circumscribed over time by the emergence of resistance and the recognition of specific, sometimes severe, toxicities, both classes retain important, albeit more selective, roles in modern therapeutics. A thorough understanding of their pharmacology is essential for clinicians to employ these agents appropriately, maximizing therapeutic benefit while minimizing patient risk.

The clinical relevance of these drugs persists. Tetracyclines are first-line agents for infections caused by rickettsiae, chlamydiae, and mycoplasmas, and are used in the management of acne, periodontal disease, and certain zoonotic infections. Chloramphenicol, despite its potential for serious hematologic toxicity, remains a critical agent for the treatment of typhoid fever, bacterial meningitis in resource-limited settings, and serious infections caused by vancomycin-resistant Enterococcus faecium (VRE) or multidrug-resistant Streptococcus pneumoniae. The importance of these antibiotics is further underscored by their role as prototypical inhibitors of bacterial protein synthesis, serving as key models for understanding antimicrobial action and resistance.

Learning Objectives

• Describe the chemical classification, spectrum of activity, and molecular mechanism of action for tetracyclines and chloramphenicol.
• Compare and contrast the pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, of the major drugs within these classes.
• Identify the approved clinical indications, common off-label uses, and the rationale for selecting these antibiotics in specific infectious scenarios.
• Analyze the spectrum of adverse effects, from common side effects to serious toxicities, with particular attention to the hematologic risks of chloramphenicol and the contraindications of tetracyclines in specific patient populations.
• Evaluate major drug-drug interactions and formulate appropriate clinical considerations for the use of these agents in pregnancy, pediatrics, and patients with organ impairment.

Classification

Tetracyclines

Tetracyclines are classified based on their duration of action and chemical structure, which influences their pharmacokinetic profile and clinical utility.

• Short-Acting (6-8 hour half-life): Tetracycline, oxytetracycline, chlortetracycline (the progenitor). These are naturally derived.
• Intermediate-Acting (12-16 hour half-life): Demeclocycline, methacycline.
• Long-Acting (16-18+ hour half-life): Doxycycline and minocycline. These are semi-synthetic derivatives and represent the most commonly used tetracyclines in contemporary practice due to superior pharmacokinetics and tolerability.
• Glycylcyclines: A related class, with tigecycline as the principal agent. It is structurally a derivative of minocycline but is classified separately due to its expanded spectrum, including activity against many tetracycline-resistant organisms, and distinct adverse effect profile.

Chemically, all tetracyclines share a hydronaphthacene nucleus, a four-ring structure. Modifications at the C5, C6, and C7 positions confer differences in lipid solubility, absorption, and anti-microbial potency.

Chloramphenicol

Chloramphenicol is a unique, simple molecule originally derived from Streptomyces venezuelae. It is a nitrobenzene derivative with a dichloroacetyl side chain. Its classification is singular, though it has prodrug forms:

• Chloramphenicol: The base compound, available in oral and intravenous formulations.
• Chloramphenicol Palmitate: An oral ester prodrug, hydrolyzed to the active form in the intestine.
• Chloramphenicol Succinate: A water-soluble prodrug for intravenous administration, requiring hydrolysis in the liver and other tissues to release active chloramphenicol.

Mechanism of Action

Tetracyclines

The primary mechanism of action of tetracyclines is the inhibition of bacterial protein synthesis. They achieve this by reversibly binding to the 30S ribosomal subunit. More specifically, tetracyclines attach to the A-site of the ribosome, a region where aminoacyl-tRNA molecules normally bind during the elongation phase of translation. This binding is thought to occur through interaction with the 16S rRNA and ribosomal protein S7. The occupation of the A-site by the antibiotic physically obstructs the docking of the incoming aminoacyl-tRNA. Consequently, the addition of new amino acids to the growing peptide chain is prevented, halting protein synthesis.

The action is bacteriostatic against most susceptible organisms, as it inhibits growth and replication without directly causing bacterial cell death. The selectivity for bacterial over mammalian cells is attributed to the active, energy-dependent transport of tetracyclines into bacterial cells, a process not present in host cells. Mammalian ribosomes (80S) also have a different structure and are not susceptible to tetracyclines at therapeutic concentrations.

Chloramphenicol

Chloramphenicol also inhibits bacterial protein synthesis but targets the 50S ribosomal subunit, distinguishing it from tetracyclines. Its precise molecular action involves binding to the peptidyl transferase center located on the 50S subunit. This center is responsible for catalyzing the formation of peptide bonds between adjacent amino acids. By binding near this active site, chloramphenicol competitively inhibits the enzymatic activity of peptidyl transferase. This inhibition prevents the transfer of the growing peptide chain from the P-site tRNA to the amino acid on the A-site tRNA, effectively freezing the elongation process.

Like tetracyclines, chloramphenicol is typically bacteriostatic against a broad range of bacteria. Its selectivity is based on the structural differences between bacterial 70S and mammalian 80S ribosomes, though it can inhibit mitochondrial protein synthesis in mammalian cells, which utilize 70S-type ribosomes. This off-target effect is the basis for some of its significant toxicities, particularly hematologic suppression.

Pharmacokinetics

Absorption

Tetracyclines: Absorption varies significantly among agents. The older tetracyclines (e.g., tetracycline, oxytetracycline) are incompletely absorbed from the gastrointestinal tract (30-70%). Absorption is markedly impaired by divalent and trivalent cations (Ca²⁺, Mg²⁺, Al³⁺, Fe^2+/3+) found in dairy products, antacids, and iron supplements, forming non-absorbable chelates. In contrast, doxycycline and minocycline are almost completely absorbed (90-100%) and their absorption is less affected by food and cations, though it is still advisable to separate administration. Tigecycline is not orally bioavailable and is administered intravenously.

Chloramphenicol: It is rapidly and completely absorbed from the gastrointestinal tract following oral administration of the base or palmitate ester. The palmitate ester requires intraluminal hydrolysis by pancreatic lipases. The intravenous succinate ester prodrug must be hydrolyzed in the liver, kidneys, and lungs to release active drug, leading to variable and sometimes unpredictable bioavailability (70-85%).

Distribution

Tetracyclines: These agents distribute widely into body tissues and fluids. They achieve good penetration into prostate, bone, dentine, enamel, and synovial fluid. A critical property is their ability to accumulate in intracellular compartments, making them effective against pathogens like Chlamydia and Rickettsia. Doxycycline and minocycline, being highly lipophilic, exhibit excellent tissue penetration, including into the cerebrospinal fluid (CSF), albeit at levels lower than serum. All tetracyclines cross the placental barrier and are secreted into breast milk.

Chloramphenicol: Chloramphenicol displays an exceptionally wide volume of distribution, penetrating effectively into all tissues and body fluids, including the eye, CSF (achieving 30-50% of serum concentrations even in the absence of inflammation), and abscess cavities. It readily crosses the blood-brain and placental barriers.

Metabolism

Tetracyclines: Most tetracyclines are not extensively metabolized. Doxycycline undergoes some enterohepatic circulation. Minocycline is metabolized to a limited degree in the liver. Tigecycline is not extensively metabolized. Renal failure does not significantly alter the half-life of doxycycline or minocycline, as non-renal clearance compensates.

Chloramphenicol: Hepatic metabolism is the primary route of elimination. The major pathway is conjugation with glucuronic acid by hepatic UDP-glucuronosyltransferases (UGT1A9, UGT2B7) to form the inactive chloramphenicol glucuronide. A small fraction undergoes reduction of the nitro group to form inactive arylamine metabolites. Hepatic dysfunction can lead to significant accumulation of the active drug.

Excretion

Tetracyclines: Excretion pathways differ. Tetracycline and oxytetracycline are eliminated primarily unchanged in the urine via glomerular filtration. Their use requires dosage adjustment in renal impairment. Doxycycline is excreted mainly in the feces via bile and direct intestinal secretion, with only a minor renal component, making it safe in renal failure. Minocycline is eliminated by hepatic metabolism and renal/biliary excretion. Tigecycline is primarily eliminated via biliary/fecal excretion, with no dosage adjustment needed for renal impairment.

Chloramphenicol: Approximately 5-15% of an administered dose is excreted unchanged in the urine via glomerular filtration. The majority (80-90%) is eliminated as the inactive glucuronide metabolite in the urine. In renal failure, the glucuronide metabolite may accumulate, but this is not considered clinically significant. However, in hepatic failure, the clearance of the active parent drug is impaired, necessitating dose reduction and therapeutic drug monitoring.

Half-life and Dosing Considerations

The half-life (t_1/2) dictates dosing frequency. Short-acting tetracyclines (t_1/2 ≈ 6-8 h) require dosing every 6 hours. Doxycycline (t_1/2 ≈ 18 h) is typically dosed every 12-24 hours, and minocycline (t_1/2 ≈ 16 h) every 12 hours. Chloramphenicol has a t_1/2 of approximately 1.5-4 hours in adults with normal hepatic function, necessitating dosing every 6 hours to maintain therapeutic serum concentrations. Therapeutic drug monitoring, aiming for peak serum concentrations of 10-20 mg/L and troughs of 5-10 mg/L, is recommended for chloramphenicol, especially in neonates, patients with liver disease, or those receiving prolonged courses, to balance efficacy and toxicity.

Therapeutic Uses/Clinical Applications

Tetracyclines

Approved Indications:

• Rickettsial Infections: First-line for Rocky Mountain spotted fever, typhus, Q fever (doxycycline).
• Chlamydial Infections: First-line for nongonococcal urethritis, pelvic inflammatory disease, lymphogranuloma venereum, psittacosis, and trachoma (doxycycline).
• Mycoplasma pneumoniae: Doxycycline is a first-line agent for community-acquired pneumonia caused by this pathogen.
• Zoonotic Infections: Tularemia, brucellosis (combined with streptomycin or rifampin), plague, anthrax (as post-exposure prophylaxis or adjunctive treatment).
• Spirochetal Infections: Alternative agent for Lyme disease (early or late), syphilis (in penicillin-allergic patients).
• Acne Vulgaris: Low-dose, long-term oral doxycycline or minocycline for moderate to severe inflammatory acne.
• Periodontal Disease: Adjunctive therapy in aggressive periodontitis.
• Malaria Prophylaxis: Doxycycline is used for prophylaxis in areas with chloroquine-resistant Plasmodium falciparum.
• Other: Treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia (as part of combination therapy), and as an alternative for Helicobacter pylori eradication.

Glycylcyclines (Tigecycline): Approved for complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. It is reserved for situations where alternative treatments are not suitable due to its unique adverse effect profile.

Chloramphenicol

Approved Indications: Its use is restricted to serious infections where the benefit outweighs the risk of potential hematologic toxicity and where safer alternatives are not available or effective.

• Typhoid Fever: Effective against Salmonella Typhi, though fluoroquinolones and third-generation cephalosporins are often preferred. It remains important in resource-limited settings and for multidrug-resistant strains.
• Bacterial Meningitis: Historically a first-line agent. Now reserved for situations where first-line agents (e.g., third-generation cephalosporins) cannot be used due to allergy or highly resistant organisms, particularly in developing countries.
• Rickettsial Infections: An alternative to tetracyclines, especially in pregnant women or young children where tetracyclines are contraindicated.
• Anaerobic Infections: Active against many anaerobes, including Bacteroides fragilis, but metronidazole and carbapenems are generally preferred.
• Vancomycin-Resistant Enterococcus (VRE): Used in combination therapy for serious VRE infections.
• Topical Use: Ophthalmic solutions are used for superficial eye infections (e.g., bacterial conjunctivitis).

Off-label Uses: May be considered for brain abscesses, cystic fibrosis exacerbations with resistant organisms, and as part of combination regimens for multidrug-resistant Acinetobacter infections.

Adverse Effects

Tetracyclines

Common Side Effects:

• Gastrointestinal: Nausea, vomiting, epigastric distress, diarrhea. These are dose-related and common with oral administration.
• Photosensitivity: A sunburn-like reaction, particularly with demeclocycline and doxycycline. Patients are advised to use sunscreen and avoid excessive sun exposure.
• Vestibular Toxicity: Dizziness, vertigo, ataxia, and tinnitus are associated with minocycline, often reversible upon discontinuation.
• Esophageal Irritation/Ulceration: Associated with doxycycline and tetracycline capsules, especially if taken with insufficient water or before lying down.

Serious/Rare Adverse Reactions:

• Hepatotoxicity: High-dose intravenous tetracycline, particularly in pregnant women or patients with renal impairment, can cause fatty liver degeneration and hepatic failure.
• Renal Toxicity: Tetracycline may exacerbate pre-existing renal failure due to its anti-anabolic effect, increasing azotemia. Outdated, degraded tetracycline can cause Fanconi-like syndrome.
• Effects on Calcifying Tissues:
  • Teeth: Permanent discoloration (yellow-gray-brown) and enamel hypoplasia when administered during tooth development (last half of pregnancy, infancy, childhood up to age 8).
  • Bone: Can be deposited in growing bone, causing temporary growth retardation. This effect is reversible upon discontinuation.
• Pseudotumor Cerebri (Benign Intracranial Hypertension): Rare, characterized by headache, blurred vision, and papilledema. More common in young women and often associated with concomitant vitamin A supplementation.
• Hypersensitivity Reactions: Skin rashes, urticaria, and rarely, anaphylaxis.
• Superinfection: Overgrowth of Candida in the oropharynx or vagina, or Clostridioides difficile-associated diarrhea.

Tigecycline-Specific Warnings: A black box warning exists for an increased risk of all-cause mortality observed in pooled clinical trials, particularly in patients with hospital-acquired pneumonia. It also carries a warning for anaphylaxis and acute pancreatitis.

Chloramphenicol

Common Side Effects:

• Gastrointestinal: Nausea, vomiting, diarrhea, glossitis.
• Bone Marrow Suppression: Two distinct types:
  • Dose-Related, Reversible Suppression: Common, affecting erythroid precursors first, leading to anemia, reticulocytopenia, and elevated serum iron. It is a direct pharmacologic effect of mitochondrial protein synthesis inhibition, is predictable, and reverses upon discontinuation.
  • Idiosyncratic, Irreversible Aplastic Anemia: Rare (estimated 1 in 25,000 to 1 in 40,000 courses) but fatal in a high percentage of cases. It is not dose-related, can occur weeks to months after therapy has ceased, and is believed to be an immune-mediated destruction of hematopoietic stem cells. This is the basis for the black box warning.

Serious/Rare Adverse Reactions:

• Gray Baby Syndrome: A potentially fatal circulatory collapse occurring in neonates, especially premature infants. It results from the inability of the immature liver to conjugate and excrete chloramphenicol, leading to toxic accumulation. Symptoms include abdominal distension, vomiting, progressive pallid cyanosis (gray color), hypothermia, irregular respiration, and cardiovascular collapse.
• Optic Neuritis: Associated with prolonged, high-dose therapy, leading to bilateral visual impairment.
• Peripheral Neuropathy: Rare.
• Hypersensitivity Reactions: Fever, macular or vesicular rashes.

Drug Interactions

Tetracyclines

Major Drug-Drug Interactions:

• Cations (Multivalent): Concurrent administration with antacids (Al³⁺, Mg²⁺, Ca²⁺), calcium supplements, iron preparations, bismuth subsalicylate, or dairy products leads to chelation and markedly reduced absorption. Administration should be separated by 2-3 hours.
• Warfarin: Tetracyclines may potentiate the anticoagulant effect by suppressing vitamin K-producing gut flora or other mechanisms, increasing the risk of bleeding. Prothrombin time (INR) should be monitored closely.
• Oral Contraceptives: There is a theoretical risk of reduced contraceptive efficacy due to altered enterohepatic circulation of estrogens, though evidence is conflicting. Use of a backup contraceptive method is often recommended.
• Methoxyflurane: Concurrent use with tetracycline may enhance nephrotoxicity.
• Isotretinoin: Concomitant use with tetracyclines increases the risk of pseudotumor cerebri.
• Penicillins: Tetracyclines, being bacteriostatic, may antagonize the bactericidal activity of penicillins in situations where rapid killing is critical (e.g., meningitis, endocarditis). Their concurrent use is generally avoided.

Contraindications: Absolute contraindication in individuals with a history of hypersensitivity to any tetracycline. Relative contraindications include pregnancy, lactation, and children under 8 years of age due to effects on teeth and bone.

Chloramphenicol

Major Drug-Drug Interactions:

• Drugs Metabolized by Hepatic Enzymes: Chloramphenicol is an inhibitor of several hepatic cytochrome P450 isoenzymes (e.g., CYP2C9, CYP3A4). It can increase serum concentrations and toxicity of:
  • Warfarin, phenytoin, tolbutamide, chlorpropamide: Increased risk of bleeding, phenytoin toxicity (nystagmus, ataxia), or hypoglycemia.
  • Cyclosporine, tacrolimus: Increased risk of nephrotoxicity and neurotoxicity.
• Drugs Causing Bone Marrow Suppression: Concomitant use with other myelosuppressive agents (e.g., chemotherapeutic drugs, zidovudine, ganciclovir, phenylbutazone) may have additive toxic effects on the bone marrow.
• Rifampin: Rifampin induces chloramphenicol metabolism, potentially leading to subtherapeutic levels.
• Vitamin B₁₂: Chloramphenicol may interfere with the hematologic response to vitamin B₁₂ in patients with pernicious anemia.
• Penicillins: Potential for antagonism, similar to tetracyclines, though data are less robust.

Contraindications: Absolute contraindications include known hypersensitivity to chloramphenicol and a history of previous chloramphenicol-induced aplastic anemia or bone marrow suppression. It is relatively contraindicated for the prophylaxis of trivial infections or the treatment of non-serious infections where less toxic alternatives exist.

Special Considerations

Use in Pregnancy and Lactation

Tetracyclines: Generally contraindicated during pregnancy (FDA Category D). They cross the placenta and can cause permanent discoloration of the deciduous teeth and inhibit fetal bone growth. Hepatic toxicity in the pregnant woman is also a risk with high doses. Tetracyclines are excreted in breast milk in low concentrations; while the risk to a nursing infant is considered low, the potential for dental staining and effects on bone growth warrants caution, and alternative agents are preferred.

Chloramphenicol: It crosses the placenta and enters fetal circulation. Use during pregnancy is generally avoided due to lack of adequate safety data and the potential risk of “gray baby syndrome” if used near term. It is excreted into breast milk and may cause bone marrow suppression in the nursing infant; therefore, breastfeeding is not recommended during therapy.

Pediatric Considerations

Tetracyclines: Contraindicated in children under 8 years of age due to the risk of permanent tooth discoloration and enamel hypoplasia. In older children, they can be used for specific indications (e.g., Rocky Mountain spotted fever, anthrax) where the benefit outweighs the risk. Doxycycline’s association with tooth staining is less than that of older tetracyclines, and short courses (≤21 days) in children under 8 are now considered acceptable by the AAP and CDC for life-threatening infections like RMSF.

Chloramphenicol: Use in neonates and infants requires extreme caution and meticulous therapeutic drug monitoring due to immature hepatic glucuronidation pathways, which predispose to “gray baby syndrome.” Dosage must be adjusted based on weight and serum concentration monitoring is mandatory. In older children, standard precautions regarding hematologic monitoring apply.

Geriatric Considerations

Age-related decline in renal function necessitates dosage adjustment for renally excreted tetracyclines (tetracycline, oxytetracycline). Doxycycline or minocycline may be preferred in the elderly with renal impairment. In geriatric patients, the risk of C. difficile infection and drug interactions (e.g., with warfarin) is heightened. For chloramphenicol, age-related hepatic changes may alter metabolism, but specific guidelines are lacking; standard monitoring for efficacy and toxicity is paramount.

Renal and Hepatic Impairment

Tetracyclines:

• Renal Impairment: Tetracycline and oxytetracycline are contraindicated as they exacerbate azotemia. Doxycycline, minocycline, and tigecycline do not require dosage adjustment in renal failure and are the agents of choice when a tetracycline is needed.
• Hepatic Impairment: High doses of tetracyclines, particularly intravenous, should be avoided due to the risk of hepatotoxicity. Caution is advised with all tetracyclines in patients with pre-existing liver disease.

Chloramphenicol:

• Renal Impairment: No dosage adjustment is typically required for the active drug, as renal excretion is minimal. However, the inactive glucuronide metabolite may accumulate, though its clinical significance is unclear.
• Hepatic Impairment: Dosage reduction is essential. The clearance of active chloramphenicol is significantly reduced, leading to a prolonged half-life and risk of toxicity (both reversible marrow suppression and Gray Baby Syndrome). Therapeutic drug monitoring is mandatory to guide dosing.

Summary/Key Points

• Tetracyclines and chloramphenicol are broad-spectrum, bacteriostatic antibiotics that inhibit bacterial protein synthesis by binding to the 30S and 50S ribosomal subunits, respectively.
• Doxycycline and minocycline are the most commonly used tetracyclines due to favorable pharmacokinetics (once/twice-daily dosing, less interaction with food/cations, and safe use in renal failure).
• Key clinical uses of tetracyclines include rickettsial, chlamydial, and mycoplasmal infections, acne, and specific zoonoses. Chloramphenicol is reserved for serious infections like typhoid fever, bacterial meningitis (where alternatives are lacking), and infections with highly resistant organisms.
• The most significant adverse effects of tetracyclines are gastrointestinal distress, photosensitivity, vestibular toxicity (minocycline), and permanent tooth discoloration in children under 8 and during pregnancy.
• Chloramphenicol carries two critical hematologic risks: a common, dose-related reversible bone marrow suppression and a rare, idiosyncratic, often fatal aplastic anemia, warranting a black box warning.
• Major drug interactions for tetracyclines involve chelation with multivalent cations, while chloramphenicol inhibits hepatic CYP450 enzymes, increasing levels of drugs like warfarin and phenytoin.
• Special population considerations are crucial: tetracyclines are generally contraindicated in pregnancy and young children; chloramphenicol requires extreme caution and therapeutic drug monitoring in neonates and patients with hepatic impairment.

Clinical Pearls

• When prescribing oral tetracyclines (except doxycycline/minocycline), instruct patients to take them on an empty stomach with a full glass of water and to avoid concomitant dairy, antacids, or iron supplements for 2-3 hours.
• For a patient presenting with a severe headache and blurred vision on long-term tetracycline therapy, particularly a young woman, consider pseudotumor cerebri and perform a fundoscopic exam to assess for papilledema.
• Chloramphenicol should not be used for trivial infections. Its use mandates a documented discussion of the risk of aplastic anemia with the patient (informed consent in many settings) and baseline plus periodic monitoring of complete blood counts.
• In a neonate or infant with suspected sepsis in a setting where chloramphenicol is the only available broad-spectrum agent, calculating the dose based on body surface area or weight and implementing rigorous therapeutic drug monitoring from the first dose are non-negotiable to prevent gray baby syndrome.
• For a penicillin-allergic patient with neurosyphilis or late Lyme disease, doxycycline is an effective alternative, but its contraindication in pregnancy necessitates the use of desensitization to penicillin or, with caution, chloramphenicol.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.